CHAPTER 6: DISCUSSION
B.5 Timing of DAA treatment under dynamic interventions in chapter 5
Solid line is treating those with suppressed HIV viral load. Short dashed line is treating those with severe fibrosis/cirrhosis. Long dashed line is treating those with suppressed HIV viral load and severe fibrosis/cirrhosis.
152 REFERENCES
Adimora, A.A. et al., 2018. Cohort Profile: The Women’s Interagency HIV Study (WIHS). International Journal of Epidemiology, Epub.
Afdhal, N. et al., 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine, 370(20), pp.1889–1898.
Allison, P.D., 2001. Missing Data, Thousand Oaks, CA.
Alter, M.J., 2006. Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatology, 44, pp.S6–S9.
Alter, M.J. et al., 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341(8), pp.556–562.
American Association for the Study of Liver Diseases & Infectious Diseases Society of America, 2017. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. When and in Whom to Initiate HCV Therapy. Available at:
https://www.hcvguidelines.org/evaluate/when-whom [Accessed February 13, 2018]. Anderson, J.P. et al., 2014. Antiretroviral therapy reduces the rate of hepatic decompensation
among HIV-and hepatitis C virus-coinfected veterans. Clinical Infectious Diseases, 58(5), pp.719–727.
Anderson, K.B., Guest, J.L. & Rimland, D., 2004. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clinical Infectious Diseases, 39(10), pp.1507–1513. Apostolova, N. et al., 2015. Efavirenz and the CNS: What we already know and questions that
need to be answered. Journal of Antimicrobial Chemotherapy, 70(10), pp.2693–2708. Armstrong, G.L. et al., 2006. The prevalence of hepatitis C virus infection in the United States,
1999 through 2002. Annals of Internal Medicine, 144(10), pp.705–714.
Athey, S., 2017. Beyond prediction: Using big data for policy problems. Science, 355(6324), pp.483–485.
Bacchetti, P. & Moss, A.R., 1989. Incubation period of AIDS in San Francisco. Nature, 338(6212), pp.251–3.
Backus, L.I. et al., 2018. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease. Hepatology, Epub.
Backus, L.I. et al., 2005. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 39(5), pp.613–619.
Bambha, K. et al., 2012. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS, 26(5), pp.599–607.
Bang, H. & Robins, J.M., 2005. Doubly robust estimation in missing data and causal inference models. Biometrics, 61(4), pp.962–972.
153
Barkan, S.E. et al., 1998. The Women’s Interagency HIV Study. Epidemiology, 9(2), pp.117– 125.
Barre-Sinoussi, F. et al., 1983. Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS). Science, 220(4599), pp.868–871. Benhamou, Y. et al., 1999. Liver fibrosis progression in human immunodeficiency virus and
hepatitis C virus coinfected patients. The Multivirc Group. Hepatology, 30(4), pp.1054– 1058.
Berenguer, J. et al., 2014. Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis. Journal of Acquired Immune Deficiency Syndromes, 66(3), pp.280–287.
Berenguer, J. et al., 2009. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human
immunodeficiency virus and hepatitis C virus. Hepatology, 50(2), pp.407–413.
Berenguer, J. et al., 2012. Sustained virological response to interferon plus ribavirin reduces non- liver-related mortality in patients coinfected with hiv and hepatitis c virus. Clinical
Infectious Diseases, 55(5), pp.728–736.
Di Bisceglie, A.M. et al., 1989. Recombinant interferon alfa therapy for chronic hepatitis C. New England Journal of Medicine, 321(22), pp.1506–1510.
Di Bisceglie, A.M. & Hoofnagle, J.H., 2002. Optimal therapy of hepatitis C. Hepatology, 36(5 I), pp.121–127.
Bonacini, M. et al., 2004. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS, 18(15), pp.2039–2045.
Branch, A.D. et al., 2012. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clinical Infectious Diseases, 55(1), pp.137–144.
Bräu, N. et al., 2006. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. Journal of Hepatology, 44(1), pp.47–55.
Breskin, A. et al., 2015. Factors Associated With Hepatitis C Infection Among HIV-Infected Men Who Have Sex With Men With No Reported Injection Drug Use in New York City, 2000-2010. Sexually Transmitted Diseases, 42(7), pp.382–386.
Breskin, A., Cole, S.R. & Westreich, D., 2018. Exploring the subtleties of inverse probability weighting and marginal structural models. Epidemiology, Epub.
Brinkman, K. et al., 1998. Adverse effects of reverse transcriptase inhibitors : mitochondrial toxicity as common pathway. AIDS Reviews, 12(May), pp.1735–1744.
Bukh, J., 2016. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology, 65(1), pp.S2–S21.
154
Burstow, N.J. et al., 2017. Hepatitis C treatment: Where are we now? International Journal of General Medicine, 10, pp.39–52.
Butt, A.A. et al., 2017. Effect of paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and
Ledipasvir/Sofosbuvir regimens on survival compared with untreated hepatitis C virus- infected persons: Results from ERCHIVES. Clinical Infectious Diseases, 65(6), pp.1006– 1011.
Center for the Analysis and Management of MACS Data, 2017. CAMACS Report Highlights, Centers for Disease Control and Prevention, 2015a. Diagnoses of HIV Infection in the United
States and Dependent Areas, 2013 HIV Surveillance Report, Volume 25. HIV Surveillance Report, 25, pp.1–82. Available at:
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2013- vol-25.pdf [Accessed March 15, 2018].
Centers for Disease Control and Prevention, 2016. Hepatitis C FAQs for the Public. Available at: https://www.cdc.gov/hepatitis/hcv/cfaq.htm [Accessed March 15, 2018].
Centers for Disease Control and Prevention, 2017a. HIV and Viral Hepatitis, Available at: https://www.cdc.gov/hiv/pdf/library/factsheets/hiv-viral-hepatitis.pdf [Accessed March 15, 2018].
Centers for Disease Control and Prevention, 2017b. HIV in the United States: At A Glance. Available at: https://www.cdc.gov/hiv/statistics/overview/ataglance.html [Accessed March 15, 2018].
Centers for Disease Control and Prevention, 2017c. Monitoring Selected National HIV Prevention and Care Objectives Using HIV Surveillance Data - United Statese and 6 Dependent Areas, 2015, Available at:
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance- supplemental-report-vol-22-2.pdf [Accessed March 19, 2018].
Centers for Disease Control and Prevention, 2015b. Testing Recommendations for Hepatitis C Virus Infection. Available at: https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm [Accessed March 19, 2018].
Centers for Disease Control and Prevention, 2015c. Trends in US. HIV Diagnoses , 2005-2014. CDC Fact Sheet. Available at: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv- data-trends-fact-sheet-508.pdf [Accessed March 19, 2018].
Centers for Disease Control and Prevention, 2017d. Viral Hepatitis. Available at: https://www.cdc.gov/hepatitis/statistics/ [Accessed March 19, 2018].
Chen, M. et al., 2016. Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database: Analysis of risk factors and survival Z. Chen, ed. PLoS ONE, 11(3), p.e0150512.
Chen, T. et al., 2009. Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐ Infected Persons Is Unrelated to HIV Disease Progression. Clinical Infectious Diseases, 49(10), pp.1605–1615.
155
Chevaliez, S. & Pawlotsky, J.M., 2006. HCV genome and life cycle. Hepatitis C Viruses: Genomes and Molecular Biology, pp.5–47.
Chu, C. & Selwyn, P.A., 2011. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. Journal of Urban Health, 88(3), pp.556–566.
Chung, R.T. et al., 2004. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351(5), pp.451–459.
Cohen, M.S. et al., 2016. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England Journal of Medicine, 375(9), pp.830–839.
Cole, S.R. et al., 2003. Effect of highly active antiretroviral therapy on time to acquired
immunodeficiency syndrome or death using marginal structural models. American Journal of Epidemiology, 158(7), pp.687–694.
Cole, S.R. & Frangakis, C.E., 2009. The Consistency Statement in Causal Inference. Epidemiology, 20(1), pp.3–5.
Cole, S.R. & Hernán, M.A., 2008. Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology, 168(6), pp.656–664.
Collins, F.S. & Varmus, H., 2015. A New Initiative on Precision Medicine. New England Journal of Medicine, 372(9), pp.793–795.
Danta, M. et al., 2007. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS, 21(8), pp.983–991.
Davis, G.L. et al., 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine, 339(21), pp.1493–1499.
Davis, G.L. et al., 1989. Treatment of chronic hepatitis C with recombinant interferon alfa. New England journal of medicine, 321(22), pp.1501–1506.
Deeks, S.G., Lewin, S.R. & Havlir, D. V, 2013. The end of AIDS: HIV infection as a chronic disease. Lancet, 382(9903), pp.1525–1533.
Denniston, M.M. et al., 2014. Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Annals of Internal Medicine, 160(5), pp.293–300.
Desquilbet, L. et al., 2007. HIV-1 infection is associated with an earlier occurrence of a
phenotype related to frailty. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 62(11), pp.1279–1286.
Dubuisson, J. & Cosset, F.L., 2014. Virology and cell biology of the hepatitis C virus life cycle - An update. Journal of Hepatology, 61(1), pp.S3–S13.
Dudley, J. et al., 1995. The multicenter AIDS cohort study: retention after 9$1/2$ years. American Journal of Epidemiology, 142(3), pp.323–330.
156
Edwards, J.K., Cole, S.R. & Westreich, D., 2015. All your data are always missing: Incorporating bias due to measurement error into the potential outcomes framework. International Journal of Epidemiology, 44(4), pp.1452–1459.
Efron, B. & Tibshirani, R., 1986. Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy. Statistical Science, 1(1), pp.54–75.
El-Serag, H.B. et al., 2005. Survival in hepatitis C and HIV co-infection: A cohort study of hospitalized veterans. Clinical Gastroenterology and Hepatology, 3(2), pp.175–183.
El-Sherif, O., Khoo, S. & Solas, C., 2015. Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection. Current Opinion in HIV and AIDS, 10(5), pp.348–354.
Erqou, S. et al., 2014. Predictors of Mortality among United States Veterans with Human
Immunodeficiency Virus and Hepatitis C Virus Coinfection. ISRN Gastroenterology, 2014, pp.1–7.
Feld, J.J. et al., 2015. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), pp.2599–2607.
Feld, J.J. & Hoofnagle, J.H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436(7053), pp.967–972.
Fischl, M.A. et al., 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 317(4), pp.185–191. Freiman, J.M. et al., 2014. Current practices of screening for incident hepatitis C virus (HCV)
infection among HIV-infected, HCV-uninfected individuals in primary care. Clinical Infectious Diseases, 59(12), pp.1686–1693.
Fried, M.W., 2002. Side effects of therapy of hepatitis C and their management. Hepatology, 36(5 I), pp.237–244.
Fuster, D. et al., 2014. Chronic hepatitis C virus infection is associated with all-cause and liver- related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction, 109(1), pp.62–70.
Gallo, R. et al., 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome. Science, 220(4599), pp.865–867.
Gilead Sciences, 2013. U.S. Food and Drug Administration Approves Gilead’s SovaldiTM
(Sofosbuvir) for the Treatment of Chronic Hepatitis C. Available at:
http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration- approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c [Accessed March 19, 2018].
Giorgi, J. V et al., 1990. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clinical Immunology and Immunopathology, 55(2), pp.173–186.
Graham, C.S. et al., 2001. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clinical infectious diseases, 33(4), pp.562–569.
157
Greenland, S., Pearl, J. & Robins, J.M., 1999. Causal diagrams for epidemiologic research. Epidemiology, 10(1), pp.37–48.
Greub, G. et al., 2000. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 356(9244), pp.1800–1805.
Gulick, R.M. et al., 2000. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Annals of Internal Medicine, 133(1), pp.35–39.
Hajarizadeh, B., Grebely, J. & Dore, G.J., 2013. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 10(9), pp.553–562.
Hammer, S.M. et al., 1997. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. New England Journal of Medicine, 337(11), pp.725–733. Harrell, F.E., 1986. DASPLINE Macro. Available at:
http://biostat.mc.vanderbilt.edu/wiki/pub/Main/SasMacros/survrisk.txt [Accessed March 19, 2018].
Hawkins, C. et al., 2016. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. Journal of Antimicrobial
Chemotherapy, 71(9), pp.2642–2645.
Hernán, M.A. et al., 2008. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology, 19(6), pp.766–779.
Hernán, M.A. & Robins, J.M., 2017. Causal inference, CRC Boca Raton, FL:
Hessol, N.A. et al., 2001. Retention of Women Enrolled in a Prospective Study of Human
Immunodeficiency Virus Infection : Impact of Race , Unstable Housing , and Use of Human Immunodeficiency Virus Therapy. American Journal of Epidemiology, 154(6), pp.563–573. High, K.P. et al., 2012. HIV and Aging. Journal of Acquired Immune Deficiency Syndromes,
60(Suppl 1), pp.S1–S18.
Ho, D.D. et al., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373(6510), pp.123–126.
Hollingsworth, T.D., Anderson, R.M. & Fraser, C., 2008. HIV-1 Transmission, by Stage of Infection. The Journal of Infectious Diseases, 198(5), pp.687–693.
Hoshida, Y. et al., 2014. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology, 61(1), pp.S79–S90.
Hubbard, A.E. & Van Der Laan, M.J., 2008. Population intervention models in causal inference. Biometrika, 95(1), pp.35–47.
Hung, C.-C. et al., 2005. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.
158
Ioannou, G.N., Green, P.K. & Berry, K., 2017. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Journal of hepatology, 68(1), pp.25–32.
Irshad, M., Mankotia, D.S. & Irshad, K., 2013. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World Journal of Gastroenterology, 19(44), pp.7896–7909. Iyengar, S. et al., 2016. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30
Countries: An Economic Analysis. PLoS Medicine, 13(5), p.e1002032.
Jackowiak, P. et al., 2014. Phylogeny and molecular evolution of the hepatitis C virus. Infection, Genetics and Evolution, 21, pp.67–82.
Jacobson, I.M. et al., 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine, 368(20), pp.1867–1877. Jacobson, I.M. et al., 2011. Telaprevir for previously untreated chronic hepatitis C virus
infection. New England Journal of Medicine, 364(25), pp.2405–2416.
Jakobsen, J.C. et al., 2017. Direct-acting antivirals for chronic hepatitis C J. C. Jakobsen, ed. Cochrane Database of Systematic Reviews, 2017(6).
Justice, A.C., 2010. HIV and aging: Time for a new paradigm. Current HIV/AIDS Reports, 7(2), pp.69–76.
Kapadia, S.N. et al., 2017. State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. Clinical Infectious Diseases, EPub.
Kaplan, E.L. & Meier, P., 1958. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53(282), pp.457–481.
Kaslow, R.A. et al., 1987. The Multicenter AIDS Cohort Study: Rationale, Organization, and Selected Characteristics of the Particpants. American Journal of Epidemiology, 126(2), pp.310–318.
Keil, A.P. et al., 2014. The parametric G-formula for time-to-event data: towards intuition with a worked example. Epidemiology, 25(6), pp.889–897.
Kim, A.Y. et al., 2009. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology, 137(3), pp.795–814.
Kim, C.W. & Chang, K.-M., 2013. Hepatitis C virus: virology and life cycle. Clinical and Molecular Hepatology, 19(1), pp.17–25.
Kirk, G.D. et al., 2013. HIV, age, and the severity of hepatitis C virus-related liver disease: A cohort study. Annals of Internal Medicine, 158(9), pp.658–667.
Kiser, J.J. & Flexner, C., 2013. Direct-acting antiviral agents for hepatitis C virus infection. Annual Review of Pharmacology and Toxicology, 53, pp.427–449.
Klein, M.B., Lalonde, R.G. & Suissa, S., 2003. The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes, 33(3), pp.365–372.
159
Klein, M.B., Rockstroh, J.K. & Wittkop, L., 2016. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Current Opinion in HIV and AIDS, 11(5), pp.521–526.
Klevens, R.M. et al., 2012. Evolving epidemiology of hepatitis C virus in the United States. Clinical Infectious Diseases, 55(suppl 1), pp.S3–S9.
Kovari, H. et al., 2015. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 63(3), pp.573–580.
Koziel, M.J. & Peters, M.G., 2007. Viral hepatitis in HIV infection. New England Journal of Medicine, 356(14), pp.1445–1454.
van der Laan, M.J. & Rubin, D., 2006. Targeted Maximum Likelihood Learning. The International Journal of Biostatistics, 2(1).
Labarga, P. et al., 2015. Long-term survival and liver-related events after pegylated
interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. Antiviral Therapy, 20(1), pp.65–72.
Lalezari, J.P. et al., 2003. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. New England Journal of Medicine, 348(22), pp.2175–2185.
Lawitz, E. et al., 2014. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet, 384(9956), pp.1756–1765.
Lawitz, E. et al., 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine, 368(20), pp.1878–1887.
Lee, L.M. et al., 2001. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA, 285(10), pp.1308–15.
Lennox, J.L. et al., 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet, 374(9692), pp.796–806.
Leone, S. et al., 2016. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response. European Journal of Clinical Microbiology & Infectious Diseases, 35(9), pp.1511–1520. Lesko, C.R. et al., 2017. Generalizing study results. Epidemiology, 28(4), pp.553–563.
Lesko, C.R. et al., 2016. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009--11. International Journal of Epidemiology, 45(1), pp.140–150.
Levy, J.A., 2009. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS, 23(2), pp.147–160.
160
Liang, T.J. et al., 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132(4), pp.296–305.